SCHEMBL6317409

SCHEMBL6317409

CN(C(=O)OC(C)(C)C)[C@@H](COCC(=O)O)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.40
ATM Q13315 1/20 0.40
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CTSS P25774 2/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSK P43235 1/20 0.39
MMP13 P45452 1/20 0.38
PTGIR P43119 1/20 0.38
PPARA Q07869 1/20 0.38
REN P00797 1/20 0.37
ACE P12821 1/20 0.37
AKT1 P31749 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7162284 1.00 MAOB (0.45) MAOBL3MBTL1ATMITGA4ITGB7
SCHEMBL7660973 0.88 L3MBTL1 (0.41) MAOBL3MBTL1ATMITGA4ITGB7
SCHEMBL7655537 0.87 TSHR (0.40) MAOBL3MBTL1ATMITGA4ITGB7
SCHEMBL27489128 0.84 ATM (0.43) L3MBTL1ATMITGA4ITGB7OPRM1
SCHEMBL6316889 0.84 ATM (0.43) L3MBTL1ATMITGA4ITGB7OPRM1
SCHEMBL8907586 0.84 L3MBTL1 (0.43) L3MBTL1ATMITGA4ITGB7OPRM1
SCHEMBL2473923 0.84 ATM (0.43) L3MBTL1ATMITGA4ITGB7OPRM1
SCHEMBL6316448 0.83 ATM (0.42) L3MBTL1ATMITGA4ITGB7OPRM1
SCHEMBL13995754 0.82 REN (0.46) L3MBTL1ATMITGA4ITGB7OPRM1
SCHEMBL24093689 0.81 ATM (0.41) L3MBTL1ATMITGA4ITGB7OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6350767-B1 GROWTH HORMONE RELEASE STIMULANT NOVO NORDISK A/S (DK) 2002-02-26 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-6013658-A ANIMAL GROWTH REGULATORS NOVO NORDISK A/S (DK) 2000-01-11 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed
WO-1996022997-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1996-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 MAOB 840/4885L3MBTL1 1220/4885ATM 4618/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR MAOB 1149/4885L3MBTL1 1103/4885ATM 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.